Advertisement
UK markets close in 43 minutes

  • FTSE 100

    8,037.47
    +13.60 (+0.17%)
     

  • FTSE 250

    19,756.46
    +157.07 (+0.80%)
     

  • AIM

    754.72
    +5.54 (+0.74%)
     

  • GBP/EUR

    1.1629
    +0.0041 (+0.35%)
     

  • GBP/USD

    1.2447
    +0.0097 (+0.79%)
     

  • Bitcoin GBP

    53,536.32
    +303.42 (+0.57%)
     

  • CMC Crypto 200

    1,437.44
    +22.68 (+1.60%)
     

  • S&P 500

    5,059.79
    +49.19 (+0.98%)
     

  • DOW

    38,448.38
    +208.40 (+0.54%)
     

  • CRUDE OIL

    82.06
    +0.16 (+0.20%)
     

  • GOLD FUTURES

    2,335.70
    -10.70 (-0.46%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     

  • DAX

    18,102.15
    +241.35 (+1.35%)
     

  • CAC 40

    8,094.75
    +54.39 (+0.68%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

Ten rivals join with NIH to search for new drugs - WSJ

Reuters - UK Focus

Feb 4 (Reuters) - Ten big rival drug companies have formed a pact to cooperate on a government-backed effort to accelerate the discovery of new drugs, the Wall Street Journal reported.

The companies and the National Institutes of Health (NIH) will share scientists, tissue and blood samples, and data, to identify targets for new drugs for diseases such as Alzheimer's, Type 2 diabetes, rheumatoid arthritis and lupus, the Journal said.

The collaboration, called the Accelerating Medicines Partnership (LSE: PA.L - news) , will cost about $230 million and involves drugmakers such as Bristol-Myers Squibb Co, Johnson & Johnson, GlaxoSmithKline (Other OTC: GLAXF - news) , Takeda Pharmaceuticals and Sanofi (NasdaqGM: GCVRZ - news) . ()

The agreement prohibits participants from using any discovery for their own drug development until the project makes data public on that discovery.

The NIH, GlaxoSmithKline, Bristol-Myers, Sanofi, Takeda, and Johnson & Johnson (NYSE: JNJ - news) could not be immediately reached for comments by Reuters.